| Source: |
| Type: |
| Power to enhance an anti cancer effect |
| 4976- | Nimb, | Nimbolide inhibits pancreatic cancer growth and metastasis through ROS-mediated apoptosis and inhibition of epithelial-to-mesenchymal transition |
| - | vitro+vivo, | PC, | NA |
| 4646- | OLEC, | Oleocanthal as a Multifunctional Anti-Cancer Agent: Mechanistic Insights, Advanced Delivery Strategies, and Synergies for Precision Oncology |
| - | Review, | Var, | NA |
| 1226- | OLST, | Knockdown of PGM1 enhances anticancer effects of orlistat in gastric cancer under glucose deprivation |
| - | vitro+vivo, | GC, | NA |
| 5936- | P, | The impact of peppermint oil on the irritable bowel syndrome: a meta-analysis of the pooled clinical data |
| - | Review, | IBD, | NA |
| 2053- | PB, | 4-Phenyl butyric acid prevents glucocorticoid-induced osteoblast apoptosis by attenuating endoplasmic reticulum stress |
| - | in-vitro, | ostP, | 3T3 |
| 2068- | PB, | Phenylbutyrate-induced glutamine depletion in humans: effect on leucine metabolism |
| - | in-vivo, | Nor, | NA |
| 2061- | PB, | Chemo, | Complementary effects of HDAC inhibitor 4-PB on gap junction communication and cellular export mechanisms support restoration of chemosensitivity of PDAC cells |
| - | in-vitro, | PC, | PANC1 | - | in-vitro, | PC, | COLO357 | - | in-vitro, | PC, | Bxpc-3 |
| 2063- | PB, | Rad, | Phenylbutyrate sensitizes human glioblastoma cells lacking wild-type p53 function to ionizing radiation |
| - | in-vitro, | GBM, | U87MG | - | NA, | NA, | U251 |
| 2065- | PB, | TMZ, | Inhibition of Mitochondria- and Endoplasmic Reticulum Stress-Mediated Autophagy Augments Temozolomide-Induced Apoptosis in Glioma Cells |
| - | in-vitro, | GBM, | NA |
| 2069- | PB, | Toxic and metabolic effect of sodium butyrate on SAS tongue cancer cells: role of cell cycle deregulation and redox changes |
| - | in-vitro, | Tong, | NA |
| 2070- | PB, | Phenylbutyrate-induced apoptosis is associated with inactivation of NF-kappaB IN HT-29 colon cancer cells |
| - | in-vitro, | CRC, | HT-29 |
| 2074- | PB, | Chemo, | The effect of combined treatment with sodium phenylbutyrate and cisplatin, erlotinib, or gefitinib on resistant NSCLC cells |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | Calu-6 | - | in-vitro, | Lung, | H1650 |
| 2077- | PB, | Butyrate induces ROS-mediated apoptosis by modulating miR-22/SIRT-1 pathway in hepatic cancer cells |
| - | in-vitro, | Liver, | HUH7 |
| 2048- | PB, | Sodium Phenylbutyrate Inhibits Tumor Growth and the Epithelial-Mesenchymal Transition of Oral Squamous Cell Carcinoma In Vitro and In Vivo |
| - | in-vitro, | OS, | CAL27 | - | in-vitro, | Oral, | HSC3 | - | in-vitro, | OS, | SCC4 | - | in-vivo, | NA, | NA |
| 2026- | PB, | Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: A dose escalation and pharmacologic study |
| - | Trial, | GBM, | NA |
| 2028- | PB, | Potential of Phenylbutyrate as Adjuvant Chemotherapy: An Overview of Cellular and Molecular Anticancer Mechanisms |
| - | Review, | Var, | NA |
| 2036- | PB, | Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate |
| - | in-vitro, | Pca, | NA | - | in-vivo, | NA, | NA |
| 2049- | PB, | Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors |
| - | Review, | Var, | NA |
| 2043- | PB, | Cisplatin, | Phenylbutyrate interferes with the Fanconi anemia and BRCA pathway and sensitizes head and neck cancer cells to cisplatin |
| - | in-vitro, | HNSCC, | UM-SCC-1 |
| 2044- | PB, | DCA, | Differential inhibition of PDKs by phenylbutyrate and enhancement of pyruvate dehydrogenase complex activity by combination with dichloroacetate |
| - | in-vivo, | NA, | NA |
| 1231- | PBG, | Caffeic acid phenethyl ester inhibits MDA-MB-231 cell proliferation in inflammatory microenvironment by suppressing glycolysis and lipid metabolism |
| - | in-vitro, | BC, | MDA-MB-231 |
| 1672- | PBG, | The Potential Use of Propolis as an Adjunctive Therapy in Breast Cancers |
| - | Review, | BC, | NA |
| 1674- | PBG, | SDT, | HPT, | Study on the effect of a triple cancer treatment of propolis, thermal cycling-hyperthermia, and low-intensity ultrasound on PANC-1 cells |
| - | in-vitro, | PC, | PANC1 | - | in-vitro, | Nor, | H6c7 |
| 1676- | PBG, | Use of Stingless Bee Propolis and Geopropolis against Cancer—A Literature Review of Preclinical Studies |
| - | Review, | Var, | NA |
| 1678- | PBG, | 5-FU, | sericin, | In vitro and in vivo anti-colorectal cancer effect of the newly synthesized sericin/propolis/fluorouracil nanoplatform through modulation of PI3K/AKT/mTOR pathway |
| - | in-vitro, | CRC, | Caco-2 | - | in-vivo, | NA, | NA |
| 1682- | PBG, | Honey, Propolis, and Royal Jelly: A Comprehensive Review of Their Biological Actions and Health Benefits |
| - | Review, | Var, | NA |
| 1648- | PBG, | Contribution of Green Propolis to the Antioxidant, Physical, and Sensory Properties of Fruity Jelly Candies Made with Sugars or Fructans |
| - | Review, | Nor, | NA |
| 1660- | PBG, | Emerging Adjuvant Therapy for Cancer: Propolis and its Constituents |
| - | Review, | Var, | NA |
| 1664- | PBG, | Anticancer Activity of Propolis and Its Compounds |
| - | Review, | Var, | NA |
| 1666- | PBG, | Molecular and Cellular Mechanisms of Propolis and Its Polyphenolic Compounds against Cancer |
| - | Review, | Var, | NA |
| 1668- | PBG, | Propolis: A Detailed Insight of Its Anticancer Molecular Mechanisms |
| - | Review, | Var, | NA |
| 2430- | PBG, | The cytotoxic effects of propolis on breast cancer cells involve PI3K/Akt and ERK1/2 pathways, mitochondrial membrane potential, and reactive oxygen species generation |
| - | in-vitro, | BC, | MDA-MB-231 |
| 4946- | PEITC, | Phenethyl Isothiocyanate Inhibits Oxidative Phosphorylation to Trigger Reactive Oxygen Species-mediated Death of Human Prostate Cancer Cells |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | PC3 |
| 4951- | PEITC, | ROS accumulation by PEITC selectively kills ovarian cancer cells via UPR-mediated apoptosis |
| - | in-vitro, | Ovarian, | PA1 | - | in-vitro, | Ovarian, | SKOV3 |
| 4953- | PEITC, | effective-in-killing">PEITC: a natural compound effective in killing primary leukemia cells and overcoming drug resistance |
| - | in-vitro, | CLL, | NA |
| 4954- | PEITC, | Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by β-phenylethyl isothiocyanate |
| - | vitro+vivo, | Ovarian, | SKOV3 |
| 4959- | PEITC, | Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast and ovarian carcinoma by targeting their stem cell compartment |
| - | in-vitro, | Ovarian, | NA |
| 4935- | PEITC, | Phenethyl Isothiocyanate Suppresses Inhibitor of Apoptosis Family Protein Expression in Prostate Cancer Cells in Culture and In Vivo |
| - | in-vivo, | Pca, | LNCaP | - | in-vivo, | Pca, | PC3 |
| 4944- | PEITC, | Phenethyl isothiocyanate induces DNA damage-associated G2/M arrest and subsequent apoptosis in oral cancer cells with varying p53 mutations |
| - | in-vitro, | Oral, | NA |
| 4926- | PEITC, | PEITC inhibits the invasion and migration of colorectal cancer cells by blocking TGF-β-induced EMT |
| - | in-vitro, | CRC, | SW48 |
| 4929- | PEITC, | PacT, | Phenethyl isothiocyanate and paclitaxel synergistically enhanced apoptosis and alpha-tubulin hyperacetylation in breast cancer cells |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
| 4934- | PEITC, | Differential induction of apoptosis in human breast cancer cell lines by phenethyl isothiocyanate, a glutathione depleting agent |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
| 4943- | PEITC, | Phenethyl isothiocyanate (PEITC) inhibits growth of ovarian cancer cells by inducing apoptosis: role of caspase and MAPK activation |
| - | in-vitro, | Ovarian, | OVCAR-3 |
| 5183- | PEITC, | Cisplatin, | Phenethyl Isothiocyanate Induces Apoptosis Through ROS Generation and Caspase-3 Activation in Cervical Cancer Cells |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Nor, | HaCaT |
| 5184- | PEITC, | Phenethyl isothiocyanate exhibits antileukemic activity in vitro and in vivo by inactivation of Akt and activation of JNK pathways |
| - | vitro+vivo, | AML, | U937 |
| 5186- | PEITC, | Phenethyl Isothiocyanate inhibits STAT3 activation in prostate cancer cells |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | LNCaP |
| 1767- | PG, | Propyl gallate induces cell death in human pulmonary fibroblast through increasing reactive oxygen species levels and depleting glutathione |
| - | in-vitro, | Nor, | NA |
| 1769- | PG, | The Anti-Apoptotic Effects of Caspase Inhibitors in Propyl Gallate-Treated Lung Cancer Cells Are Related to Changes in Reactive Oxygen Species and Glutathione Levels |
| - | in-vitro, | Lung, | Calu-6 | - | in-vitro, | Lung, | A549 |
| 1770- | PG, | Propyl gallate sensitizes human lung cancer cells to cisplatin-induced apoptosis by targeting heme oxygenase-1 for TRC8-mediated degradation |
| - | in-vitro, | Lung, | NA |
| 1765- | PG, | Enhanced cell death effects of MAP kinase inhibitors in propyl gallate-treated lung cancer cells are related to increased ROS levels and GSH depletion |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | Calu-6 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:961 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid